Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emicizumab

Roche Basel Switzerland

Roche keeps Venclexta train rolling with new leukaemia filing

The drug could treat AML patients who are ineligible for chemotherapy

- PMLiVE

NHS England says yes to Roche’s Hemlibra

But stalls on funding for Actelion's Uptravi

- PMLiVE

Roche reshuffles its executive committee, again

Sophie Kornowski-Bonnet joins Reed and heads for the exit

Roche Basel Switzerland

Roche agrees $2.4bn takeover of genomics player Foundation

Offers a 29% premium on the Foundation’s recent share price

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

- PMLiVE

AbbVie trial backs chemo-free Imbruvica combo regimen

Imbruvica paired with Roche’s Gazyva for previously untreated CLL patients

- PMLiVE

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

A rapid round up from the frontline of pharma, biotech and healthcare

- PMLiVE

More encouraging data for Spark and Pfizer’s potential haemophilia B cure

Pfizer set to commence phase III trials

- PMLiVE

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Latest data could unlock a new patient population for the Swiss pharma giant’s injection

- PMLiVE

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

A rapid round-up of pharma, biotech and healthcare news

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links